Tandem Diabetes Care (Nasdaq:TNDM) filed an SEC Form 8-K announcing its chief commercial officer’s intent to resign.
Brian B. Hansen, EVP and CCO, notified the company of his decision to resign on Aug. 17. His resignation goes into effect on Dec. 31, 2023.
In connection with Hansen’s resignation, he and the automated insulin delivery technology maker entered into a separation agreement. Under this agreement, dated Aug. 18, Hansen remains employed until June 28, 2024. However, he will be on administrative leave after the Dec. 31, 2023, effective date.
Along with receiving his base salary through the separation date, Hansen remains entitled to a cash bonus as determined by the company. He also stands to receive COBRA premiums for up to six months following the effective date. Tandem said that equity awards by held by Hansen continue to vest through the separation date, too.
Hansen became EVP and CCO at Tandem Diabetes Care in February 2016. Before joining the company, he served as chief commercial officer at Adaptive Biotechnologies, starting in September 2014. Prior to that, he was head of commercial, sales and marketing at Novartis’ Genoptix.
From December 2005 to February 2013, Hansen held a number of roles of increasing responsibility at Gen-Probe. That stint culminated in his serving as SVP, global sales and services from January 2012 to February 2013.
Tandem Diabetes Care develops automated insulin delivery products, including its flagship t:slim X2 pump with Control-IQ technology. The company last month won FDA clearance for its Mobi automated insulin delivery system, which is less than half the size of the t:slim X2.
The company also recently announced a new, limited-time offer for its Tandem Choice technology access program. This program now provides new and renewing, eligible users of its t:slim X2 pump a pathway to new offerings like Mobi.